The U.S. Centers for Disease Control and Prevention (CDC) on Aug. 3 recommended using a new monoclonal antibody from Sanofi and AstraZeneca to protect infants against respiratory syncytial virus (RSV). The CDC's advisory committee voted unanimously to include the nirsevimab ...